Cogent director sells 45K shares after option exercise
Cogent Biosciences, Inc. (COGT) director Arlene Morris reported option exercises and related share sales in Cogent Biosciences stock.
Rhea-AI Filing Summary
Cogent Biosciences, Inc. (COGT) director Arlene Morris reported option exercises and related share sales in Cogent Biosciences stock. On 2026-08-27 she exercised stock options for 45,510 shares of common stock (41,927 at an exercise price of $5.64 per share and 3,583 at $2.52 per share), from fully vested awards. The same day she sold 45,510 shares of common stock in open-market transactions at weighted average prices of $37.0925 and $37.5396 per share, with actual sale prices ranging from $36.46–$37.65 per share. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 45,510 shares ($1.44M approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Morris Arlene
Role
Director
Sold
45,510 shs ($1.69M)
Approx. gross sale proceeds
$1.69M
Approx. exercise cost
$245K
Approx. pre-tax spread
$1.44M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F4 | 41,927 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F1, F4 | 3,583 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 41,927 | $5.64 | $236K |
| Exercise | Common Stock F1 | 3,583 | $2.52 | $9K |
| Sale | Common Stock F1, F2 | 42,349 | $37.0925 | $1.57M |
| Sale | Common Stock F1, F3 | 3,161 | $37.5396 | $119K |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,773 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
- F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F4. These options are fully vested.
Key Figures
Options exercised (shares): 41,927 shares
Exercise price per share: $5.64 per share
Options exercised (additional): 3,583 shares
+5 more
8 metrics
Options exercised (shares)
41,927 shares
Stock options exercised at an exercise price of $5.64 per share on 2026-08-27
Exercise price per share
$5.64 per share
Exercise price for 41,927 option shares of Cogent Biosciences common stock
Options exercised (additional)
3,583 shares
Stock options exercised at an exercise price of $2.52 per share on 2026-08-27
Exercise price per share (additional)
$2.52 per share
Exercise price for 3,583 option shares of Cogent Biosciences common stock
Shares sold (first sale)
42,349 shares
Common stock sold at a weighted average price of $37.0925 per share
Weighted average sale price (first sale)
$37.0925 per share
Shares sold in multiple transactions between $36.46 and $37.45 per share
Shares sold (second sale)
3,161 shares
Common stock sold at a weighted average price of $37.5396 per share
Weighted average sale price (second sale)
$37.5396 per share
Shares sold in multiple transactions between $37.46 and $37.65 per share
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), weighted average sale price per share, derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"Transactions effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did Cogent Biosciences (COGT) director Arlene Morris report on this Form 4?
She reported exercising stock options for 45,510 shares of Cogent Biosciences common stock and selling 45,510 shares of common stock in open-market transactions on 2026-08-27, all under a Rule 10b5-1 trading plan adopted on May 28, 2026.
How many Cogent Biosciences (COGT) options did Arlene Morris exercise and at what prices?
She exercised options covering 41,927 shares at an exercise price of $5.64 per share and 3,583 shares at an exercise price of $2.52 per share, for a total of 45,510 option shares converted into Cogent Biosciences common stock.
Were Arlene Morris’s Cogent Biosciences (COGT) trades under a Rule 10b5-1 plan?
Yes. The Form 4 indicates the trades were effected pursuant to a Rule 10b5-1 trading plan adopted by Arlene Morris on May 28, 2026, and the Rule 10b5-1 checkbox is marked as affirmed.
Were the options exercised by Arlene Morris in Cogent Biosciences (COGT) fully vested?
Yes. A footnote states that the stock options exercised for 41,927 shares at $5.64 and 3,583 shares at $2.52 were fully vested at the time of exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
